# Part D

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/part-d
Canonical HTML page: https://getbiobrief.com/entity/part-d

## Recent coverage (1 stories)

### Medicare Part D Subsidy Ends: How Pharma & Biotech Face a $3.6B Shift in Patient Costs
2026-07-30 21:24:46 · Sentiment: Bearish · Impact: 7/10 · Sources: 5

Termination of the temporary Medicare Part D subsidy by the Trump administration could shift $3.6 billion in costs, affecting drug pricing dynamics and patient adherence, with implications for pharma and biotech companies reliant on senior populations.
Full story: https://getbiobrief.com/story/medicare-part-d-subsidy-pharma-biotech-impact

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.